Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer.


SCHEDULE 13G




Comment for Type of Reporting Person:  Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer.


SCHEDULE 13G




Comment for Type of Reporting Person:  Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer.


SCHEDULE 13G




Comment for Type of Reporting Person:  Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer.


SCHEDULE 13G




Comment for Type of Reporting Person:  Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer.


SCHEDULE 13G




Comment for Type of Reporting Person:  Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer.


SCHEDULE 13G




Comment for Type of Reporting Person:  Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer.


SCHEDULE 13G




Comment for Type of Reporting Person:  Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer.


SCHEDULE 13G



 
YA II PN, Ltd.
 
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:06/24/2025
 
YA Global Investments II (U.S.), LP
 
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:06/24/2025
 
Yorkville Advisors Global, LP
 
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:06/24/2025
 
Yorkville Advisors Global II, LLC
 
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:06/24/2025
 
YAII GP, LP
 
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:06/24/2025
 
YAII GP II, LLC
 
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:06/24/2025
 
Mark Angelo
 
Signature:/s/ Mark Angelo
Name/Title:Mark Angelo
Date:06/24/2025
 
SC-Sigma Global Partners, LP
 
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:06/24/2025